Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
|
CN |
|
P
|
Promimic AB
STO:PRO
|
SE |
|
Charter Hall Retail REIT
ASX:CQR
|
AU |
|
B
|
BCPL Railway Infrastructure Ltd
BSE:542057
|
IN |
|
Shenzhen Yinghe Technology Co Ltd
SZSE:300457
|
CN |
|
Prism Johnson Ltd
NSE:PRSMJOHNSN
|
IN |
|
V
|
VerticalScope Holdings Inc
TSX:FORA
|
CA |
Relative Value
The Relative Value of one Sunshine Guojian Pharmaceutical Shanghai Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 69.94 CNY, Sunshine Guojian Pharmaceutical Shanghai Co Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
Competitors Multiples
Sunshine Guojian Pharmaceutical Shanghai Co Ltd Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
S
|
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
SSE:688336
|
43.2B CNY | 34.8 | 56.4 | 165.4 | 165.4 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |